Evidence map›Paper›PMID 34987643›Full record

ReviewTheranostics2022

Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.

Cassandra Miller, Julie Rousseau, Caterina F Ramogida, Anna Celler, Arman Rahmim, Carlos F Uribe

Open access · goldAbstract readReview
In one paragraph

Review in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 56 citations in OpenAlex.

  1. [Research square · 2026
    Article
  2. Picolinamide-functionalized macrocyclic chelators forInorganic chemistry frontiers · 2026
    Article
  3. CXCR4-targeted PET imaging of glioblastoma using [EJNMMI radiopharmacy and chemistry · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Radiotheranostic landscape: A review of clinical and preclinical development.European journal of nuclear medicine and molecular imaging · 2025
    Review
  18. Review
  19. Dosimetry Software for Theranostic Applications: Current Capabilities and Future Prospects.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Cassandra MillerDepartment of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.
Julie RousseauDepartment of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.
Caterina F RamogidaDepartment of Chemistry, Simon Fraser University, Burnaby, BC, Canada.
Anna CellerDepartment of Radiology, University of British Columbia, Vancouver, BC, Canada.
Arman RahmimDepartment of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.
Carlos F UribeDepartment of Radiology, University of British Columbia, Vancouver, BC, Canada.
University of British Columbia · CATRIUMF · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Theranostics is an emerging paradigm that combines imaging and therapy in order to personalize patient treatment. In nuclear medicine, this is achieved by using radiopharmaceuticals that target identical molecular targets for both imaging (using emitted gamma rays) and radiopharmaceutical therapy (using emitted beta, alpha or Auger-electron particles) for the treatment of various diseases, such as cancer. If the therapeutic radiopharmaceutical cannot be imaged quantitatively, a "theranostic pair" imaging surrogate can be used to predict the absorbed radiation doses from the therapeutic radiopharmaceutical. However, theranostic dosimetry assumes that the pharmacokinetics and biodistributions of both radiopharmaceuticals in the pair are identical or very similar, an assumption that still requires further validation for many theranostic pairs. In this review, we consider both same-element and different-element theranostic pairs and attempt to determine if factors exist which may cause inaccurate dose extrapolations in theranostic dosimetry, either intrinsic (e.g. chemical differences) or extrinsic (e.g. injecting different amounts of each radiopharmaceutical) to the radiopharmaceuticals. We discuss the basis behind theranostic dosimetry and present common theranostic pairs and their therapeutic applications in oncology. We investigate general factors that could create alterations in the behavior of the radiopharmaceuticals or the quantitative accuracy of imaging them. Finally, we attempt to determine if there is evidence showing some specific pairs as suitable for theranostic dosimetry. We show that there are a variety of intrinsic and extrinsic factors which can significantly alter the behavior among pairs of radiopharmaceuticals, even if they belong to the same chemical element. More research is needed to determine the impact of these factors on theranostic dosimetry estimates and on patient outcomes, and how to correctly account for them.

Indexed as

AnimalsHumansNeoplasmsNuclear MedicineRadionuclide ImagingRadiopharmaceuticalsTheranostic NanomedicineRadiopharmaceuticalsdosimetrypersonalized medicineradiopharmaceuticalsradiopharmaceutical therapytheranostics

Identifiers

PMID34987643
PMCPMC8690938
OpenAlexW3213800578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.